New Therapeutic Strategies for Lymphoma
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 399
Special Issue Editor
Special Issue Information
Dear Colleagues,
Lymphoma treatment has seen a revolution over the past 5 years with the development and approval of novel therapeutic strategies including chimeric antigen receptor T-cell therapy, bispecific antibodies, antibody–drug conjugates, monoclonal antibodies, immune checkpoint inhibitors, and molecular targeted therapies. Novel approaches to the timing and potential combinations of these therapies are areas of active study. The optimal strategies appear to be disease- and disease-subtype-specific and benefits appear to vary based on disease-specific characteristics. For example, large B cell lymphoma and follicular lymphoma have been inundated with novel CAR T therapies and bispecific antibody treatment options, while mantle cell lymphoma has seen both CAR T and molecular targeted therapies showing benefits. Despite these advances, diseases including peripheral T cell lymphomas have only had modest advancement with efficacy seen with targeted therapy and epigenetic modifying agents. In addition, although these advances have drastically changed the therapeutic landscape of lymphoma in general, there is still significant room for improvement. Novel therapies in this setting would be considered those beyond the recent advancements that have become standard practice. These would include novel cellular therapeutics beyond CD19-targeted CAR T including novel targeting CAR T product and novel cellular products such as CAR NK as well as novel monoclonal and bispecific and trispecific antibodies and combinations beyond the well-described CD20 monoclonal and bispecific antibodies that are well known. Novel molecular targets beyond the well-known Bruton's tyrosine kinase, phosphoinositide-3-kinase, BCL2 inhibitors, or novel combinations of these agents would also be of interest.
Original research and review articles on new therapeutic strategies for Lymphoma are welcome to this special issue.
Dr. Geoffrey Shouse
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chimeric antigen receptor
- immunotherapy
- bispecific antibody
- trispecific antibody
- antibody–drug conjugate
- immune checkpoint
- molecular targeted therapy
- epigenetic modifiers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
